Regeneron (REGN) came out with quarterly earnings of $12.89 per share, beating the Zacks Consensus Estimate of $8.03 per ...

Regeneron Pharmaceuticals beat Wall Street estimates for second-quarter revenue and profit on Friday helped by robust demand ...

Regeneron Pharmaceuticals delivered strong Q2 results and made net progress with its commercial portfolio and pipeline. Click ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock has underperformed the medical sector and S&P 500 Index in this timeframe.

Regeneron Pharmaceuticals has a price-to-sales (P/S) ratio of 4.6 versus a figure of 3.0 for the S&P 500 Moreover, the company’s price-to-free cash flow (P/FCF) ratio stands at 16.4 in contrast ...

This new investment underscores Regeneron’s commitment to deliver innovative medicines to patients. Regeneron continues to invest heavily in its New York State operations, where an approximately ...

The Tarrytown, New York-based company said it had profit of $12.81 per share. Earnings, adjusted for one-time gains and costs, were $12.89 per share. The results exceeded Wall Street expectations. The ...